TrialAnnals of hematology2021

Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.

Xiao-Lin Yuan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.